National Health Service

The National Health Service enters the account of psychedelic research at two concrete points: it employed clinical psychologist Rosalind Watts before she joined a psilocybin depression study, and it approved Robin Carhart-Harris’s 2009 study of psilocybin’s effects on the brain. Together, these details place the NHS within the institutional passage from conventional mental-health work to experimental psychedelic research, while the evidence does not identify it as the trial’s operator or establish a wider NHS policy on psychedelic therapy.

Institutional role and scope

The NHS is not presented through a description of its organization, services, or formal position on psychedelics. Its significance here is specific rather than comprehensive. It appears first as Watts’s employer before her move into research, and later among the authorities whose approval was required for a brain-imaging experiment. The account therefore links the service to both clinical employment and the regulation of research, but does not show that these two roles were part of a coordinated NHS program.

That limited framing matters. The book describes psychedelic therapy as a practice that unsettles established distinctions between medicine and spirituality, and raises questions about how much of a treatment’s effect comes from the drug, the guide, a patient’s expectations, or the setting. Those wider arguments provide context for the NHS’s appearance, but they should not be mistaken for an account of NHS policy or practice.

Approval of brain-imaging research

In 2009, Carhart-Harris, then working in David Nutt’s laboratory and supported by Amanda Feilding, received approval from the NHS and the Home Office to investigate psilocybin’s effects on the brain. The study marked a move from the group’s earlier work toward research directly involving a classic psychedelic. Carhart-Harris volunteered to receive the drug first, reasoning that researchers asking other people to take it and enter a scanner should be willing to undergo the procedure themselves. Nutt discouraged him, both because Carhart-Harris described himself as anxious and because participating could compromise his objectivity. A colleague became the first volunteer to receive psilocybin and undergo fMRI scanning.

The experiment also challenged an expectation about what researchers would see. Carhart-Harris had anticipated increased activity, especially in emotional regions, but the first results showed reduced blood flow. A second measure, based on oxygen consumption, supported that finding. The reduction was concentrated in the default mode network, then little known to Carhart-Harris. The NHS’s documented role is the approval that helped make this research possible; the account does not specify the details of its review or attribute the scientific findings to the service.

A clinician’s route into psychedelic research

Watts provides a separate link between the NHS and the renewed clinical investigation of psychedelics. While working as a young clinical psychologist for the service, she read an article about psychedelic therapy and was struck by the possibility of treating mental illness rather than only managing symptoms. She wrote to Carhart-Harris, who brought her into the depression study, the laboratory’s first venture into clinical research.

Watts guided several sessions and interviewed all the volunteers six months after treatment. Her work shifted attention from symptom scores alone to how participants described their lives and the changes they experienced. They characterized depression as disconnection: from other people, former selves, feelings, beliefs, spiritual values, and nature. Some described mental imprisonment or repetitive rumination; one said that orchids could be recognized intellectually as beautiful without their beauty being felt. These interviews made Watts’s contribution one of interpretation and follow-up, as well as session guidance. The evidence establishes her NHS employment before this transition, but does not say that the service sponsored her move or the study.

Clinical research at an institutional boundary

The two NHS references reveal different forms of connection to psychedelic research. In Carhart-Harris’s case, the service appears in a chain of official approvals alongside the Home Office. In Watts’s, it is the workplace from which a clinical psychologist moved toward a research role. Neither reference, by itself, demonstrates that psychedelic therapy had become routine NHS treatment or that the organization adopted a general position on it.

That distinction sits within a broader tension in the account. Psychedelic studies ask conventional medicine to evaluate experiences shaped not only by pharmacology but also by expectations, therapeutic relationships, and setting; blinding participants can be difficult because they may recognize whether they received psilocybin or a placebo. The NHS’s documented approvals and employment connection show points of institutional contact with this emerging field, while leaving the larger questions of clinical adoption, treatment standards, and the place of spiritual experience unresolved.